Myasthenia Gravis (Chronic Weakness) Clinical Trials

A listing of Myasthenia Gravis (Chronic Weakness) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 28 clinical trials
A Study of TAK-079 in People With Generalized Myasthenia Gravis

Myasthenia gravis is an autoimmune condition that causes muscle weakness. Autoimmune means the body makes antibodies that attack its own cells and tissues. These types of antibodies are also known as autoantibodies. People with generalized myasthenia gravis have a weakness in many muscles. TAK-079 is a medicine to help people …

azathioprine
anticholinesterase agents
tacrolimus
cholinesterase
weakness
  • 22 views
  • 02 Apr, 2021
  • 59 locations
Safety Tolerability and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks.

immunosuppressive agents
serologic test
corticosteroids
generalized myasthenia gravis
ra101495
  • 97 views
  • 30 Jul, 2021
  • 160 locations
Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis

The purpose of this study is to investigate the Pharmacodynamics (PD), Pharmacokinetics (PK), safety, tolerability, immunogenicity, and clinical efficacy of efgartigimod coformulated with recombinant human hyaluronidase PH20 (rHuPH20) as compared to efgartigimod IV infused in patients with generalized myasthenia gravis (gMG). The study duration is approximately 12 weeks. After screening, …

generalized myasthenia gravis
  • 0 views
  • 30 Jul, 2021
  • 38 locations
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

The purpose of the MycarinGstudy is to demonstrate the clinical efficacy and to assess safety and tolerability of rozanolixizumab in patients with generalized myasthenia gravis (MG).

immune globulin
igiv
plasma exchange
generalized myasthenia gravis
immunoglobulin g (igg)
  • 76 views
  • 01 Aug, 2021
  • 131 locations
Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis

The purpose of this study is to evaluate the long-term safety and tolerability of efgartigimod PH20 SC 1000 mg, and the clinical efficacy, PD, pharmacokinetics (PK), immunogenicity, impact on the quality of life (QoL) of the participants, treatment satisfaction, and administration method preference, and the feasibility of self- and caregiver-supported …

immune globulin
immunoglobulin g (igg)
generalized myasthenia gravis
acetylcholine
  • 0 views
  • 09 Jul, 2021
  • 8 locations
Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis

This study examines the effect of adjuvant therapy with the oral beta-agonist Salbutamol in patients with generalized myasthenia gravis on stable standard of care having residual symptoms.

salbutamol 4mg tablet
salbutamol
generalized myasthenia gravis
repetitive nerve stimulation
immunomodulator
  • 15 views
  • 24 Jan, 2021
  • 2 locations
Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis

A randomized, placebo-controlled, double-blinded cross-over study evaluating and quantifying the effect of pyridostigmine on muscle strength and symptoms in Myasthenia Gravis (MG)

pyridostigmine
mestinon
  • 5 views
  • 22 Jan, 2021
  • 1 location
Subcutaneous Immunoglobulin for Myasthenia Gravis

This is a prospective open-label, randomized, parallel arm clinical trial. The primary objective of the study is to evaluate the safety and efficacy of Cuvitru 20% subcutaneous immunoglobulin in patients with myasthenia gravis (MG). The secondary objective is to evaluate patient preferences and effects on quality of life when treating …

  • 0 views
  • 03 Feb, 2021
  • 1 location
Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis

This is a phase II, single center, randomized, double-blind, placebo-controlled, study in patients with a diagnosis of anti-AchR antibody positive myasthenia gravis.

  • 0 views
  • 17 Apr, 2021
  • 1 location
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

This is a Phase Ib/IIa study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis

generalized myasthenia gravis
immunosuppressive agents
  • 0 views
  • 17 Feb, 2021
  • 4 locations